Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578053 | 0.86 | FEN1 (0.46) | KDM4EALDH1A1MAPTMAPK1FEN1 | |
| SCHEMBL30918929 | 0.86 | FEN1 (0.46) | KDM4EALDH1A1MAPTMAPK1FEN1 | |
| SCHEMBL30918933 | 0.81 | LMNA (0.53) | KDM4EALDH1A1GAALMNAHPGD | |
| SCHEMBL9952845 | 0.79 | LMNA (0.49) | ALDH1A1MAPTMAPK1LMNAHPGD | |
| SCHEMBL5789983 | 0.79 | TYMS (0.39) | KDM4ELMNAMEN1KMT2A | |
| SCHEMBL1747974 | 0.76 | KDM4E (0.42) | KDM4EALDH1A1MAPTMAPK1ACHE | |
| SCHEMBL578430 | 0.74 | TUBB4A (0.55) | KDM4E | |
| SCHEMBL577953 | 0.73 | NPC1 (0.52) | KDM4EALDH1A1MAPTGLAGAA | |
| SCHEMBL30014118 | 0.73 | NPC1 (0.52) | KDM4EALDH1A1MAPTGLAGAA | |
| SCHEMBL1747975 | 0.72 | ALPL (0.56) | ALDH1A1MPOMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073823-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-8580804-B2 | Compound having hetero ring skeleton, and process for producing optically active compound using the aforementioned compound as asymmetric catalyst | KYOTO UNIVERSITY (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-19 | — | — | US | disclosed |
| EP-2418204-B1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | UNIV KYOTO (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2418204-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | Kyoto University (JP) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245257-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | COASY, LSS, INF2 | KDM4E 2092/4885ALDH1A1 2537/4885MAPT 47/4885 |
| US-20120095227-A1 | COMPOUND HAVING HETERO RING SKELETON, AND PROCESS FOR PRODUCING OPTICALLY ACTIVE COMPOUND USING THE AFOREMENTIONED COMPOUND AS ASYMMETRIC CATALYST | CCNL2, ASH2L, AHR | KDM4E 2110/4885ALDH1A1 2003/4885MAPT 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.